The present meta-analysis was undertaken to (1) assess erythroid response rates in
myelodysplastic syndromes (MDS) patients treated with epoetin alfa as a monotherapy,(2) …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which
has negative consequences. Erythropoiesis‐stimulating agents (ESA s) and their biosimilars …

Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This
double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS …

We analyzed prognostic factors of response, response duration, and possible impact on
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony …

Purpose To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating
factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic …

Overview T he myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies
with relatively heterogeneous spectrums of presentation. The major clinical problems in …

This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of
erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive …

The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively
heterogeneous spectrums of presentation. The major clinical problems in these disorders …

Anemia is common in Myelodysplastic Syndromes (MDS). Different anemia treatments have
been tested in clinical studies, but the full impact on patients' health-related quality of life …